ABL1 | ABL proto-oncogene 1, non-receptor tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
ADA | Adenosine deaminase | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
AKR1D1 | Aldo-keto reductase family 1, member D1 | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enriched |
ANXA1 | Annexin A1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Transporters
| | | | | Expressed in all |
APEX1 | APEX nuclease (multifunctional DNA repair enzyme) 1 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
ATIC | 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
ATP6V1B2 | ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 | FDA approved drug targets Predicted intracellular proteins Transporters
| | | | | Expressed in all |
BLVRB | Biliverdin reductase B (flavin reductase (NADPH)) | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CAT | Catalase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
CD44 | CD44 molecule (Indian blood group) | Blood group antigen proteins Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CES1 | Carboxylesterase 1 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
CKB | Creatine kinase, brain | Cancer-related genes Candidate cardiovascular disease genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
CPT1A | Carnitine palmitoyltransferase 1A (liver) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CPT2 | Carnitine palmitoyltransferase 2 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
DHODH | Dihydroorotate dehydrogenase (quinone) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
DNMT1 | DNA (cytosine-5-)-methyltransferase 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
EGFR | Epidermal growth factor receptor | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
FASN | Fatty acid synthase | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
FGF1 | Fibroblast growth factor 1 (acidic) | Cancer-related genes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Group enriched |
GANAB | Glucosidase, alpha; neutral AB | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
GSR | Glutathione reductase | Cancer-related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
HDAC1 | Histone deacetylase 1 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
HDAC2 | Histone deacetylase 2 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
HDAC3 | Histone deacetylase 3 | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
HMMR | Hyaluronan-mediated motility receptor (RHAMM) | CD markers FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
HPRT1 | Hypoxanthine phosphoribosyltransferase 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
IKBKB | Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
ITGA2B | Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) | Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
JUN | Jun proto-oncogene | Cancer-related genes FDA approved drug targets Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
MAOA | Monoamine oxidase A | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | | | | Mixed |
MAP2 | Microtubule-associated protein 2 | FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
MAP2K1 | Mitogen-activated protein kinase kinase 1 | Cancer-related genes Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
MAP2K2 | Mitogen-activated protein kinase kinase 2 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
MAP4 | Microtubule-associated protein 4 | FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
MAPK1 | Mitogen-activated protein kinase 1 | Cancer-related genes Cytoskeleton related proteins Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
MAPK3 | Mitogen-activated protein kinase 3 | Cancer-related genes Cytoskeleton related proteins Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Expressed in all |
METAP2 | Methionyl aminopeptidase 2 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
NFKB1 | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins RAS pathway related proteins Transcription factors
| | | | | Expressed in all |
NR3C1 | Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) | Disease related genes FDA approved drug targets Nuclear receptors Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Expressed in all |
PLA2G4A | Phospholipase A2, group IVA (cytosolic, calcium-dependent) | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins RAS pathway related proteins
| | | | | Mixed |
POLA1 | Polymerase (DNA directed), alpha 1, catalytic subunit | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
PRDX5 | Peroxiredoxin 5 | Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PRKAA1 | Protein kinase, AMP-activated, alpha 1 catalytic subunit | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
PRKAB1 | Protein kinase, AMP-activated, beta 1 non-catalytic subunit | FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
PSMB1 | Proteasome (prosome, macropain) subunit, beta type, 1 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PSMB10 | Proteasome (prosome, macropain) subunit, beta type, 10 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PSMB9 | Proteasome (prosome, macropain) subunit, beta type, 9 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
PTGS1 | Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) | Cancer-related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
RARB | Retinoic acid receptor, beta | Cancer-related genes Disease related genes FDA approved drug targets Nuclear receptors Predicted intracellular proteins Transcription factors
| | | | | Mixed |